The companies plan to enhance the platform’s capabilities in the biologics drug discovery space through their partnership.
PerkinElmer announced it is expanding its documentation, workflow, and decision-making Signals informatics platform to enhance its capabilities in the biologics drug discovery space following a collaboration with Insightful Science, a life sciences software company.
The platform expansion will include the offering of SnapGene and Geneious Prime software for DNA construct design, molecular cloning, and other kinds of molecular biology research; the ability to access and compare data across experiments and instruments; and the option to replicate assays and experiments immediately, PerkinElmer said in a March 17, 2021 company press release.
“There is a limited availability of IT tools in the biologics space,” said Kevin Willoe, vice-president and general manager of PerkinElmer, Informatics, in the press release. “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately—important capabilities when fighting foes like cancer, cardio, neurological, and viral diseases.”
"The integration of best-in-class scientific software with cloud-based data platforms is increasingly essential for modern pharmaceutical and biotech enterprises to streamline research and ensure the integrity of valuable data,” added Brett Ammundsen, CEO Bioinformatics at Insightful Science, in the press release. “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus on producing life-changing outcomes.”
Source: PerkinElmer
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.